---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-002329"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:31:25.785951+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports no difference between neflamapimod and placebo in DLB trial; OLE data expected Q1 2025

## Summary
- No discernible differences between neflamapimod 40mg TID and placebo during 16-week double-blind phase of RewinD-LB trial.
- Measured trough plasma concentrations similar to 40mg BID in prior Alzheimer's study, lower than targeted.
- Retrospective analysis suggests lower bioavailability related to age of drug batch used in double-blind phase.
- PK data from food-effect study and within-subject comparison (13 participants) indicate newer capsules achieved target concentrations.
- Topline data from first 16 weeks of open-label extension (OLE) phase expected in Q1 2025.

## SEC filing metadata
- accession: 0001437749-25-002329
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/0001437749-25-002329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925002329/crvo20250130_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-002329
- JSON: https://secwatch.observer/filing/0001437749-25-002329.json
- Plain text: https://secwatch.observer/filing/0001437749-25-002329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.